Clinical Study of Cannabidiol (CBD) in Children and Adolescents with Fragile X

Clinical Trial Summary

CONNECT-FX (Clinical Study of Cannabidiol (CBD) in Children and Adolescents with Fragile X) is a multi-national, randomized, double-blind, placebo-controlled, 14-week trial, sponsored by Zynerba Pharmaceuticals. It is enrolling patients ages 3 through 17 years with full mutation Fragile X syndrome, to evaluate the efficacy and safety of an investigational CBD gel (ZYN002).
 
CONNECT-FX is evaluating a novel transdermally (on the skin) delivered CBD (ZYN002) for some common and debilitating behaviors associated with FXS.

Trial Locations

The trial will include 204 patients (children and adolescents ages three through 17 years) at approximately 20 clinical sites in the United States, Australia and New Zealand who have been diagnosed with FXS.

Enrollment Information

1-833-FXSTUDY
(1-833-397-8839)